BeOne

Q3 2026 RESULTS

Q3 FINANCIALS

Q3 Revenue

$1.9B

+34% from prior-year period

Net Income

$385M

GAAP diluted earnings per ADS of $3.28

Gross Margin

88%

from 86% prior-year period

COMMERCIAL HIGHLIGHTS

Brukinsa® zanubrutinib

+34%*

U.S. FDA Priority Review designation for Phase 3 MANGROVE filing

TEVIMBRA (tislelizumab)

+28%*

Japan regulatory approval; U.S. FDA approval for TEVIMBRA-based regimen in HER2+ GEA

PIPELINE & PARTNERSHIP HIGHLIGHTS

- 45 accepted abstracts and five oral presentations accepted at ASH
- Five pivotal-stage programs advancing across solid tumor portfolio
- Collaboration with Revolution Medicines to evaluate combinations and expand access to RAS(ON) inhibitors in Asian markets

CANCER HAS NO BORDERS NEITHER DO WE

*Compared to prior-year period